Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Philip Thomas
Ut Southwestern Medical Center, Department: Physiology
Should you be removed from our database? Contact us at [email protected]. Read more below.
ReCode Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
See attachment.
DEVELOPMENT OF MEMBRANE PROTEIN STRUCTURE
RELEVANCE (See instructions): Most cases of cystic fibrosis, a common fatal genetic disease, are caused by mutations that interfere with the assembly of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The studies proposed will elucidate the details of how the disease-causing mutations interfere with this process. Understanding the assembly process, and, thus, the detailed molecular pathology, will provide important information for developing targeted therapeutics for cystic fibrosis.
Filed on May 31, 2017.
Tell us what you know about Philip Thomas's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Philip Thomas filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Philip Thomas | Ut Southwestern Medical Center | Conflict of Interest | Reata Pharmaceuticals | $550,000 - $599,999 |
| Philip Thomas | Ut Southwestern Medical Center | Conflict of Interest | ReCode Therapeutics | $20,000 - $39,999 |
| Philip Thomas | Ut Southwestern Medical Center | Conflict of Interest | ReCode Therapeutics | $0 - $4,999 |
| Philip Thomas | Ut Southwestern Medical Center | Conflict of Interest | ReCode Therapeutics | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.